Shots:
- EYE PCR has received the CE Mark under EU MDR for fixOflex endocapsular device for use during cataract surgery
- fixOflex has shown comparable safety to standard cataract surgery in a study of 121 pts, with 0.83% PCO incidence at 12mos. vs 13% in a retrospective control group, & no Nd:YAG capsulotomies required compared to three in controls
- fixOflex is designed to preserve capsular bag integrity & intracapsular space during & after cataract surgery, helping to optimize the optical performance in pts
Ref: PRnewswire | Image: EYE PCR | Press Release
Related News: Encora Therapeutics’ Encora X1 Gains the US FDA 510(k) Clearance for Essential Tremor
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
